Bayer Continuing Vitrakvi Studies to Improve Understanding of ...

Given the rarity of NTRK fusions, the company is also rolling out a free testing program to identify NTRK fusion-positive patients who would ...

Bayer to present extensive new data from its oncology portfolio at ...

Bayer will reveal late-breaking data from the Phase III ARANOTE trial in metastatic hormone-sensitive prostate cancer for darolutamide ...

Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy ...

In an updated analysis on the adult subset of non-central nervous system (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, ...

Efficacy of Vitrakvi™ further established with continued high ... - Bayer

... understanding of quality of life results for the majority of ... The trials are still ongoing, with the latest dataset published in ...

Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical ...

The trials are still ongoing, with the latest dataset published ... Bayer focuses its research activities on first-in-class innovations ...

FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK ...

Bayer Continuing Vitrakvi Studies to Improve Understanding of Activity In Specific Tumor Types. Charlotte Hu, Precision Medicine Online, 2020.

Bayer United States of America - The Efficacy of Vitrakvi ...

“With more patients added and a longer follow-up, we continue to see efficacy and a consistent safety profile for larotrectinib, regardless of tumor types, in ...

ArcherDx, Bayer Partner on NGS-Based Companion Diagnostic Test ...

Bayer Continuing Vitrakvi Studies to Improve Understanding of Activity In Specific Tumor Types. Charlotte Hu, Precision Medicine Online, 2020. Bayer, Leica ...

Follow-Up Data on Bayer's Larotrectinib Hints at Potentially Curative ...

Updates on Bayer's Vitrakvi (larotrectinib) were presented ... Updates on the ongoing trial announced at ASCO include that “we've continued ...

Patient Info on Effectiveness Data | VITRAKVI® (larotrectinib)

There are ongoing studies to confirm the benefit of VITRAKVI for this use. NTRK, neurotrophic receptor tyrosine kinase; TRK, tropomyosin receptor kinase ...

Bayer to Present New Prostate Cancer Data and Continued ...

Bayer will present primary results from the Phase III ARANOTE trial in metastatic hormone-sensitive prostate cancer (mHSPC) for NUBEQA® ...

VITRAKVI® (larotrectinib) | Official Patient Website

Learn about VITRAKVI® (larotrectinib), a treatment for NTRK gene fusion positive solid tumors. Visit the official patient site to see safety and full ...

Long-term Data on Vitrakvi® (larotrectinib) Further Demonstrate ...

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.1. “This ...

Bayer and ArcherDX Announce Global Collaboration to Develop ...

Collaboration will focus on development of a companion diagnostic (CDx) for Vitrakvi®, the first-in-class tyrosine kinase (TRK) inhibitor ...

NDA 211710 Oral Solution Vitrakvi Draft ... - Bayer

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 2. DOSAGE AND ...

Bayer's 'tumor-agnostic' cancer med Vitrakvi turned away in England ...

... trials with other treatments.” The drug ... Merck joins American Lung Association in raising awareness of pulmonary arterial hypertension.

Bayer And Foundation Medicine Announce Global Collaboration To ...

The first project will be to develop a companion diagnostic for Vitrakvi® (larotrectinib), the first and only TRK inhibitor approved in the ...

Vitrakvi, INN-larotrectinib - European Medicines Agency

clinical studies in adult and paediatric cancer patients (Table 5). The studies are still ongoing. Patients with and without documented NTRK gene fusion ...

Bayer presents latest data from oncology portfolio at 2024 ASCO ...

An overview of the ongoing investigational Phase III ARASTEP trial ... VITRAKVI in clinical trials (NCT02122913, NCT02576431, NCT02637687).

Patient Stories | Vitrakvi® (larotrectinib) | Patient Site

Sharing your voice can help others take control of their cancer diagnosis and better understand their options. ... There are ongoing studies to confirm the ...